BioCryst Pharmaceuticals, Inc. BCRX and privately held Presidio
Pharmaceuticals, Inc. today announced the mutual termination of the
Merger Agreement and the related Investor Financing Agreement entered
into on October 17, 2012. Although the original rationale for the merger
had merit, the parties determined that terminating the merger was in the
best interest of both companies and their respective shareholders at
this time.
The termination of the transaction has been approved by the Boards of
both companies. In association with the termination, both parties will
release each other from all obligations with respect to the proposed
transaction. Each company will bear its own legal and transaction fees.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in